Dyslipidemia

Data from the REMAP-CAP trial suggests use of aspirin or P2Y12 inhibitors had a low likelihood of improving organ support-free days in critically ill patients with COVID-19 within 21 days compared to no antiplatelet therapy.

Results of the meta-analysis indicate the absolute risk reductions seen with statin therapy were notably lower than the relative risk reductions achieved with statin therapy.

An analysis of data from a prospective stroke registry suggests presence of hypertriglyceridemia was associated with a more than 2-fold increase in risk of MACE among patients with a history of acute stroke or TIA, even with adjustment for baseline LDL-C and statin use.

A new study suggests use of apixaban was associated with a lower rate of rehospitalization for VTE compared with warfarin in patients with VTE requiring extended anticoagulation.

A meta-analysis of data from more than 4 million patients suggests the prevalence of statin therapy may be overdiagnosed and provides insight into risk factors associated with increased risk of intolerance.

Findings from REDUCE-IT show icosapent ethyl was projected to be cost-effective compared with standard care in patients with high CV risk despite statin therapy.

A new study in JAMA Network Open provides an overview of the cost-effectiveness of icosapent ethyl at multiple prices in high-risk patients with hypertriglyceridemia despite statin therapy.

An international, retrospective analysis presented at ISC 2022 provides evidence suggesting use of DOACs as a treatment for cerebral venous thrombosis was associated with similar risk of recurrent clots and death as warfarin, but a 65% lower risk of major bleeding.

Analysis of real-world registry data presented at ISC 2022 provide insight into the risk of intracranial hemorrhage with tenecteplase versus alteplase in patients with acute ischemic stroke.

Data from an analysis of the ALSPAC cohort suggests arterial stiffness in adolescence could cause insulin resistance and dyslipidemia in young adulthood.

Abbott's device is designed to create highly detailed 3-dimensional maps of the heart to help physicians identify and treat abnormal rhythms.

Announced on December 22, the approval of inclisiran (Leqvio) comes nearly a year after the original PDUFA date. With approval, inclisiran becomes the first and only siRNA therapy approved to lower LDL-C with twice-yearly dosing.

Announced on Dec. 20, the latest approvals for rivaroxaban (Xarelto) mark the 10th and 11th indications for the factor Xa inhibitor in the US.

Data from an analysis of 67k older Danes suggests statin discontinuation corresponded with 1 excess event per 112 persons per year in a primary prevention cohort and 1 excess event per 77 persons per year in a secondary prevention cohort.

The Practical Cardiology editorial staff has compiled a list of 6 noteworthy posters related to cardiology from the Metabolic Institute of America's 19th annual World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease.

November's cardiology month in review features stories from the AHA's late-breaking sessions and Kidney Week 2021.

Every year, AHA Scientific Sessions provides clinicians and researchers with a glimpse into the latest data from clinical trials. Our editorial staff's top picks for late-breaking data from AHA 2021 Scientific Sessions includes AVATAR, RAPID CABG, REVERSE-IT, and more.

Deepak Bhatt, MD, MPH, discusses the results of the interim analysis of the REVERSE-IT trial presented at AHA 2021, which indicates bentracimab provided immediate and sustained reversal of ticagrelor's antiplatelet effects in patients requiring urgent surgery or experiencing major bleeding.

After 2 years, there was little difference in cognitive function between patients with nonvalvular atrial fibrillation receiving dabigatran or warfarin in the GIRAF trial, which was presented at AHA 2021.

Using data from more than 80k matched pairs of statin users and comparators, investigators from UT Southwestern Medical Center found initiation of statin therapy was associated with an increased likelihood of diabetes progression, including risk of hyperglycemia and ketoacidosis.

An analysis of NHANES data presented at EASD 2021 suggests a return to a healthy weight in patients with obesity could result in reverse some of the cardiovascular risk associated with obesity, including high blood pressure and cholesterol disorders.

Announced on September 24, the approval is for use as an adjunct to diet and other LDL-C-lowering therapies for reducing LDL-C in patients aged 10 years and older with heterozygous familial hypercholesterolemia.

Results of the TWILIGHT-Stent study provide insight into the impact of stent type on effects of ticagrelor monotherapy compared against ticagrelor plus aspirin among patients within the original TWILIGHT trial.

TWILIGHT-HBR suggests ticagrelor monotherapy could lower bleeding risk among patients meeting ARC-HBR criteria. Study presenter Davide Cao, MD, offers further perspective on results of the post hoc analysis.

An ESC Congress 2021 analysis suggests icosapent ethyl was associated with a 35% reduction in total primary end point events among patients with a history of myocardial infarction prior to enrollment in the REDUCE-IT trial.

Results of MASTER DAPT demonstrate an abbreviated period of DAPT rather than a standard approach preserves ischemic benefits and reduces bleeding risk in patients at a high bleeding risk following stent implantation.

Announced on August 24, rivaroxaban (Xarelto) has received its ninth indication from the US FDA. This time, the FDA has approved a label expansion to include patients with symptomatic peripheral artery disease who have undergone lower extremity revascularization.

Using propensity score-matching, a new study is providing insight into the risk reduction and bleeding risk associated with various DOACs versus warfarin and one another in patients with nonvalvular atrial fibrillation and an increased gastrointestinal bleeding risk.

A trio of trials examine whether or not heparin could provide relief of COVID-19 symptoms in patients with varying levels of disease severity.

An analysis of data from the COMPASS study suggests the addition of low-dose rivaroxaban to aspirin resulted in benefits, irrespective of concomitant therapies or comorbidities.